Evidence map›Paper›PMID 37461253›Full record

ArticleClinical and translational medicine2023

Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti-programmed death receptor ligand 1 therapy response of triple-negative breast cancer.

Xi Chen, Yuanliang Yan, Wangrui Liu, Yuanhong Liu, Abhimanyu Thakur, Qiuju Liang, Zhijie Xu

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xi ChenDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0009-0005-2765-6653
Yuanliang YanDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0001-6610-3617
Wangrui LiuRenji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-0459-4446
Yuanhong LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Abhimanyu ThakurPritzker School of Molecular Engineering, Ben May Department for Cancer Research, University of Chicago, Chicago, Illinois, USA.
Qiuju LiangDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.
Zhijie XuDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.ORCID https://orcid.org/0000-0003-2047-883X
Central South University · CNShanghai Jiao Tong University · CNUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

T-LymphocytesTriple Negative Breast NeoplasmsHumansLigandsReceptors, Death DomainLigandsReceptors, Death Domain

Identifiers

PMID37461253
PMCPMC10352603
OpenAlexW4384627466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.